Th17 and cancer: friends or foes? ----------------------------------------------------------------------------------------------------------------Vincenzo Bronte ISTITUTO ONCOLOGICO VENETO
Adoptive transfer of tumor-reactive CD8 ϩ T lymphocytes is one of the most effective immunotherapy approaches for the treatment of solid tumors. 1 Muranski and colleagues show that a recently identified population of CD4 ϩ T lymphocytes called Th17 cells possesses unexpected antimyeloma therapeutic properties.
I
n mammals, CD4 ϩ T lymphocytes are central elements of cell-mediated immunity, recruiting and directing other cells of both the innate and the acquired immune system toward antigens. Humans must cope with exposure to many different pathogens, which require diversified effector mechanisms in order to be properly eliminated. Evolution has addressed this environmental complexity by increasing the complexity of effector CD4 ϩ T cells, and at least 4 main subsets have been described to date: Th1, Th2, Th17, and T regulatory cells (T regs ). 2 Through the activation of peculiar transcription factors, cytokines mediate the transition from naive CD4 ϩ T cells into one of these subsets, often simultaneously inhibiting other differentiation pathways. 2 Th17 cells represent the latest addition to this group. Their differentiation is driven primarily by TGF-␤ and IL-6 cytokines, whereas IL-23, originally thought to be the master regulator, seems to be important for maintenance of Th17 responses. Th17 cells release IL-17 and IL-22, and are implicated in the induction of numerous autoimmune and inflammatory responses. 2 The information about the relevance of this cell subset in cancer biology is scant and contradictory. IL-23 has been shown to promote tumor growth and impair antitumor CD8 ϩ T cells 3 but, on the other hand, dendritic cells transduced with IL-23 have been described as triggering powerful antitumor activity. 4 These discrepancies might result from the oftdescribed dichotomous nature of the effects of endogenous production as compared with unregulated engineered release of the same cytokine. However, the effects of IL-23 alone cannot be taken as a bona fide demonstration of Th17 cell involvement. Indeed, few reports have addressed the presence of Th17 cells in experimental and human tumors, 5 and none provide a clear indication about either a protumoral or antitumoral activity.
Muranski and colleagues used transgenic mice expressing a high-affinity T-cell receptor (TCR) specific for an epitope of the melanoma antigen known as tyrosinase-related protein 1 (TRP-1). Exploiting different polarizing culture conditions in vitro, the authors drove TRP-1-specific CD4 ϩ T cells toward either Th0, Th1, or Th17 cells. Upon adoptive transfer in mice bearing established cutaneous melanomas, Th17 cells were shown to be superior in mediating both rejection of established melanoma and autoimmune vitiligo. Interestingly, therapeutic activity depended on Th17-cell release of IFN-␥, rather than IL-17 and IL-23 production, even though Th1-polarized cells produced more IFN-␥ than Th17 effectors. Muranski and colleagues do not clarify whether the polarizing regimen promoted differentiation of multiple cell subsets; nonetheless, they provide relevant perspectives for adoptive immunotherapy of cancer. Optimization of culture conditions to polarize human CD4 ϩ T cells to Th17 cells with heightened antitumor activity (possibly dependent on high affinity of the TCR) and tumor specificity will require further efforts. It would certainly help to identify the tumor antigens recognized by tumor-infiltrating Th17 cells.
The findings of Muranski and coworkers raise some interesting questions. If Th17 cells are so effective in destroying tissues, what limits their armamentarium during tumor development? Do T regs play a role, as suggested by some studies 5 ? For clinical translation, it will also be extremely important to understand whether concomitant autoimmunity can be controlled or mitigated, if this approach is to be extended to tumors other than melanomas.
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Unsweetened Notch leads to myeloproliferation --------------------------------------------------------------------------------
These results raise a number of interesting questions. All 4 receptors should be unfucosylated in FX Ϫ/Ϫ mice, but it is not known which Notch receptor is responsible for suppression of myeloproliferation. As mentioned, modification of O-fucose by Fringe modulates Notch activity. In the absence of Fringe, Ofucose remains a monosaccharide, but in the presence of Fringe it is elongated to a tetrasaccharide. The relevant structures of the Ofucose glycans that are lost in FX Ϫ/Ϫ mice are unknown. Because O-fucosylation of EGF repeat 12 in Notch1 plays such an important role in T-cell development, it would be interesting to know if loss of this specific fucose also suppresses myelogenesis. The future of Notch and hematopoiesis certainly looks sweet.
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A report in this issue of Blood reveals novel, unexpected regulatory mechanisms of the chemokine universe.
C
hemokines are a complex superfamily of molecules that guide trafficking and positioning of hematopoietic and nonhematopoietic cells. In this issue of Blood, Cardona and colleagues show that mice genetically deficient in representative members of chemokine receptor classes have high levels of cognate ligands in blood and in inflamed tissues. Altered levels of promiscuous ligands perturb the system by affecting other receptors. This and previous scattered reports 1 suggest that signaling chemokine receptors internalize and scavenge cognate ligands, thus acting as rheostats and tuners of the system. These findings have broad implications for pathophysiology, interpretation of receptor-gene targeting experiments, and assessment of pharmacological inhibitors.
The chemokine system is a complex universe consisting of 42 genes encoding ligands and 20 signaling receptors, both having splice and processing variants; it also includes "silent" receptors that have alterations in sequence motifs essential for signaling (eg, the so-called DRY motif in the second intracellular loop), distinct spectra of ligands recognized, and peculiar tissue distribution, and can act as professional decoys and scavengers 2, 3 (see figure) . D6 binds most inflammatory CC chemokines, that is, those produced in response to inflammatory, immunological, or microbiological stimuli (eg, CCL2/MCP-1). CCX CKR binds homeostatic CC chemokines, which guide trafficking of lymphocytes to lymph nodes (eg, CCL19/ELC and CCL21/SLC). The Duffy Antigen Receptor for Chemokines (DARC; also known as Duffy antigen) binds inflammatory CC and CXC chemokines, and in addition to ligand degradation, it may also act as a facilitator of chemokine transfer across cellular barriers. Strong genetic data indicate that D6, CCX CKR, and to some extent, DARC are decoys and scavengers for chemokines that tune leukocyte trafficking under inflammatory (D6) and homeostatic (CCX CKR) conditions, 2-4 and recent evidence indicates that CXCR7, the second receptor for CXCL12/SDF1, also sharpens chemokine concentration and focuses the migration of zebrafish primordial germ cells by means of ligand scavenging. 5 Thus, professional decoy receptors play an essential tuning role in the chemokine system; this paradigm could also extend beyond the chemokine system, as some evidence that the C5a receptor 
